CN109652484A - 一种全细胞高效催化合成l-肌肽的方法 - Google Patents
一种全细胞高效催化合成l-肌肽的方法 Download PDFInfo
- Publication number
- CN109652484A CN109652484A CN201910040744.9A CN201910040744A CN109652484A CN 109652484 A CN109652484 A CN 109652484A CN 201910040744 A CN201910040744 A CN 201910040744A CN 109652484 A CN109652484 A CN 109652484A
- Authority
- CN
- China
- Prior art keywords
- beta
- histidine
- alanyl
- ala
- synthesizes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 title claims abstract description 45
- 108010087806 Carnosine Proteins 0.000 title claims abstract description 44
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 29
- 241000588724 Escherichia coli Species 0.000 claims abstract description 26
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims abstract description 21
- 238000005215 recombination Methods 0.000 claims abstract description 20
- 230000006798 recombination Effects 0.000 claims abstract description 20
- 229940024606 amino acid Drugs 0.000 claims abstract description 15
- 150000001413 amino acids Chemical class 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 229960002885 histidine Drugs 0.000 claims abstract description 13
- 108700016155 Acyl transferases Proteins 0.000 claims abstract description 9
- 239000000758 substrate Substances 0.000 claims abstract description 9
- 239000007853 buffer solution Substances 0.000 claims abstract description 7
- 239000013598 vector Substances 0.000 claims abstract description 7
- UZCXPYDBYUEZCV-UHFFFAOYSA-N methyl 3-aminopropanoate Chemical class COC(=O)CCN UZCXPYDBYUEZCV-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002773 nucleotide Substances 0.000 claims abstract description 6
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 10
- 102000057234 Acyl transferases Human genes 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 3
- 238000005457 optimization Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000012137 tryptone Substances 0.000 claims description 3
- 230000003519 ventilatory effect Effects 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 210000002429 large intestine Anatomy 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- 241000305071 Enterobacterales Species 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 210000004209 hair Anatomy 0.000 claims 1
- 102000004400 Aminopeptidases Human genes 0.000 abstract description 9
- 108090000915 Aminopeptidases Proteins 0.000 abstract description 9
- 102000004190 Enzymes Human genes 0.000 abstract description 8
- 108090000790 Enzymes Proteins 0.000 abstract description 8
- 230000003197 catalytic effect Effects 0.000 abstract description 6
- 238000000746 purification Methods 0.000 abstract description 5
- 239000003054 catalyst Substances 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 239000013612 plasmid Substances 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 17
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 229940000635 beta-alanine Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 5
- 238000006555 catalytic reaction Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- -1 sodium alkoxide Chemical class 0.000 description 4
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 3
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 3
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 3
- QXPRJQPCFXMCIY-NKWVEPMBSA-N Gly-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN QXPRJQPCFXMCIY-NKWVEPMBSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- SLUWOCTZVGMURC-BFHQHQDPSA-N Thr-Gly-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O SLUWOCTZVGMURC-BFHQHQDPSA-N 0.000 description 3
- 229940044199 carnosine Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108010090894 prolylleucine Proteins 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 2
- XCZXVTHYGSMQGH-NAKRPEOUSA-N Ala-Ile-Met Chemical compound C[C@H]([NH3+])C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C([O-])=O XCZXVTHYGSMQGH-NAKRPEOUSA-N 0.000 description 2
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 description 2
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 2
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 241000589586 Empedobacter brevis Species 0.000 description 2
- SSFWXSNOKDZNHY-QXEWZRGKSA-N Gly-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN SSFWXSNOKDZNHY-QXEWZRGKSA-N 0.000 description 2
- YBKKLDBBPFIXBQ-MBLNEYKQSA-N Ile-Thr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)O)N YBKKLDBBPFIXBQ-MBLNEYKQSA-N 0.000 description 2
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 2
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 2
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 2
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 2
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 2
- RFKVQLIXNVEOMB-WEDXCCLWSA-N Thr-Leu-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N)O RFKVQLIXNVEOMB-WEDXCCLWSA-N 0.000 description 2
- WTMPKZWHRCMMMT-KZVJFYERSA-N Thr-Pro-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WTMPKZWHRCMMMT-KZVJFYERSA-N 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 108010020688 glycylhistidine Proteins 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- CWFMWBHMIMNZLN-NAKRPEOUSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CWFMWBHMIMNZLN-NAKRPEOUSA-N 0.000 description 1
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 1
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- WUHJHHGYVVJMQE-BJDJZHNGSA-N Ala-Leu-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WUHJHHGYVVJMQE-BJDJZHNGSA-N 0.000 description 1
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 1
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
- FFZJHQODAYHGPO-KZVJFYERSA-N Ala-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N FFZJHQODAYHGPO-KZVJFYERSA-N 0.000 description 1
- YHBDGLZYNIARKJ-GUBZILKMSA-N Ala-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N YHBDGLZYNIARKJ-GUBZILKMSA-N 0.000 description 1
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 1
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 1
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 1
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PHONXOACARQMPM-BQBZGAKWSA-N Gly-Ala-Met Chemical compound [H]NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O PHONXOACARQMPM-BQBZGAKWSA-N 0.000 description 1
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 1
- QSDKBRMVXSWAQE-BFHQHQDPSA-N Gly-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN QSDKBRMVXSWAQE-BFHQHQDPSA-N 0.000 description 1
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 1
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 1
- HMHRTKOWRUPPNU-RCOVLWMOSA-N Gly-Ile-Gly Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O HMHRTKOWRUPPNU-RCOVLWMOSA-N 0.000 description 1
- LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 description 1
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 1
- OCPPBNKYGYSLOE-IUCAKERBSA-N Gly-Pro-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN OCPPBNKYGYSLOE-IUCAKERBSA-N 0.000 description 1
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 1
- DCRODRAURLJOFY-XPUUQOCRSA-N His-Ala-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)NCC(O)=O DCRODRAURLJOFY-XPUUQOCRSA-N 0.000 description 1
- ZVKDCQVQTGYBQT-LSJOCFKGSA-N His-Pro-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O ZVKDCQVQTGYBQT-LSJOCFKGSA-N 0.000 description 1
- MDOBWSFNSNPENN-PMVVWTBXSA-N His-Thr-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O MDOBWSFNSNPENN-PMVVWTBXSA-N 0.000 description 1
- UPJODPVSKKWGDQ-KLHWPWHYSA-N His-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N)O UPJODPVSKKWGDQ-KLHWPWHYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- MQFGXJNSUJTXDT-QSFUFRPTSA-N Ile-Gly-Ile Chemical compound N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)O MQFGXJNSUJTXDT-QSFUFRPTSA-N 0.000 description 1
- NYEYYMLUABXDMC-NHCYSSNCSA-N Ile-Gly-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)N NYEYYMLUABXDMC-NHCYSSNCSA-N 0.000 description 1
- VOBYAKCXGQQFLR-LSJOCFKGSA-N Ile-Gly-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O VOBYAKCXGQQFLR-LSJOCFKGSA-N 0.000 description 1
- MASWXTFJVNRZPT-NAKRPEOUSA-N Ile-Met-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)O)N MASWXTFJVNRZPT-NAKRPEOUSA-N 0.000 description 1
- RQJUKVXWAKJDBW-SVSWQMSJSA-N Ile-Ser-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N RQJUKVXWAKJDBW-SVSWQMSJSA-N 0.000 description 1
- GMUYXHHJAGQHGB-TUBUOCAGSA-N Ile-Thr-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N GMUYXHHJAGQHGB-TUBUOCAGSA-N 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- CCLQKVKJOGVQLU-QMMMGPOBSA-N L-homocarnosine Chemical compound NCCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 CCLQKVKJOGVQLU-QMMMGPOBSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
- WSGXUIQTEZDVHJ-GARJFASQSA-N Leu-Ala-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O WSGXUIQTEZDVHJ-GARJFASQSA-N 0.000 description 1
- XBBKIIGCUMBKCO-JXUBOQSCSA-N Leu-Ala-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XBBKIIGCUMBKCO-JXUBOQSCSA-N 0.000 description 1
- HYMLKESRWLZDBR-WEDXCCLWSA-N Leu-Gly-Thr Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HYMLKESRWLZDBR-WEDXCCLWSA-N 0.000 description 1
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 1
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- URHJPNHRQMQGOZ-RHYQMDGZSA-N Leu-Thr-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O URHJPNHRQMQGOZ-RHYQMDGZSA-N 0.000 description 1
- GAELMDJMQDUDLJ-BQBZGAKWSA-N Met-Ala-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O GAELMDJMQDUDLJ-BQBZGAKWSA-N 0.000 description 1
- MVBZBRKNZVJEKK-DTWKUNHWSA-N Met-Gly-Pro Chemical compound CSCC[C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N MVBZBRKNZVJEKK-DTWKUNHWSA-N 0.000 description 1
- NDJSSFWDYDUQID-YTWAJWBKSA-N Met-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N)O NDJSSFWDYDUQID-YTWAJWBKSA-N 0.000 description 1
- YGNUDKAPJARTEM-GUBZILKMSA-N Met-Val-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O YGNUDKAPJARTEM-GUBZILKMSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- HFZNNDWPHBRNPV-KZVJFYERSA-N Pro-Ala-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HFZNNDWPHBRNPV-KZVJFYERSA-N 0.000 description 1
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 1
- AFXCXDQNRXTSBD-FJXKBIBVSA-N Pro-Gly-Thr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O AFXCXDQNRXTSBD-FJXKBIBVSA-N 0.000 description 1
- HAEGAELAYWSUNC-WPRPVWTQSA-N Pro-Gly-Val Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAEGAELAYWSUNC-WPRPVWTQSA-N 0.000 description 1
- FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 description 1
- MCWHYUWXVNRXFV-RWMBFGLXSA-N Pro-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 MCWHYUWXVNRXFV-RWMBFGLXSA-N 0.000 description 1
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 1
- CGSOWZUPLOKYOR-AVGNSLFASA-N Pro-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 CGSOWZUPLOKYOR-AVGNSLFASA-N 0.000 description 1
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 1
- GZNYIXWOIUFLGO-ZJDVBMNYSA-N Pro-Thr-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZNYIXWOIUFLGO-ZJDVBMNYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- BRKHVZNDAOMAHX-BIIVOSGPSA-N Ser-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N BRKHVZNDAOMAHX-BIIVOSGPSA-N 0.000 description 1
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 1
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 1
- QQWNRERCGGZOKG-WEDXCCLWSA-N Thr-Gly-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O QQWNRERCGGZOKG-WEDXCCLWSA-N 0.000 description 1
- DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 1
- JKGGPMOUIAAJAA-YEPSODPASA-N Thr-Gly-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O JKGGPMOUIAAJAA-YEPSODPASA-N 0.000 description 1
- YJCVECXVYHZOBK-KNZXXDILSA-N Thr-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H]([C@@H](C)O)N YJCVECXVYHZOBK-KNZXXDILSA-N 0.000 description 1
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 1
- SIEZEMFJLYRUMK-YTWAJWBKSA-N Thr-Met-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N)O SIEZEMFJLYRUMK-YTWAJWBKSA-N 0.000 description 1
- JAJOFWABAUKAEJ-QTKMDUPCSA-N Thr-Pro-His Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O JAJOFWABAUKAEJ-QTKMDUPCSA-N 0.000 description 1
- VTMGKRABARCZAX-OSUNSFLBSA-N Thr-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O VTMGKRABARCZAX-OSUNSFLBSA-N 0.000 description 1
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 1
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 1
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 1
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 1
- ZLFHAAGHGQBQQN-AEJSXWLSSA-N Val-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZLFHAAGHGQBQQN-AEJSXWLSSA-N 0.000 description 1
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 description 1
- AZSHAZJLOZQYAY-FXQIFTODSA-N Val-Ala-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O AZSHAZJLOZQYAY-FXQIFTODSA-N 0.000 description 1
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 1
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 1
- ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 1
- MJFSRZZJQWZHFQ-SRVKXCTJSA-N Val-Met-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)O)N MJFSRZZJQWZHFQ-SRVKXCTJSA-N 0.000 description 1
- XBJKAZATRJBDCU-GUBZILKMSA-N Val-Pro-Ala Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O XBJKAZATRJBDCU-GUBZILKMSA-N 0.000 description 1
- MIKHIIQMRFYVOR-RCWTZXSCSA-N Val-Pro-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)N)O MIKHIIQMRFYVOR-RCWTZXSCSA-N 0.000 description 1
- YQYFYUSYEDNLSD-YEPSODPASA-N Val-Thr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O YQYFYUSYEDNLSD-YEPSODPASA-N 0.000 description 1
- JAIZPWVHPQRYOU-ZJDVBMNYSA-N Val-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O JAIZPWVHPQRYOU-ZJDVBMNYSA-N 0.000 description 1
- BDKZHNJTLHOSDW-UHFFFAOYSA-N [Na].CC(O)=O Chemical compound [Na].CC(O)=O BDKZHNJTLHOSDW-UHFFFAOYSA-N 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000007036 catalytic synthesis reaction Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 108010054812 diprotin A Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 1
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 108700002498 homocarnosine Proteins 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 1
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了一种全细胞高效催化合成L‑肌肽的方法,包括以下步骤:1)构建重组载体,所述重组载体含有核苷酸序列为SEQ ID NO.1所示的氨基酸脂酰基转移酶基因,该基因编码的氨基酸序列如SEQ ID NO.2所示;2)将核苷酸序列SEQ ID NO.1所示的基因转入大肠杆菌获得重组大肠杆菌;3)将底物β‑丙氨酸甲酯以及L‑组氨酸溶于缓冲溶液,pH值为7.5‑9.5;4)将重组大肠杆菌加入缓冲溶液中进行反应,反应温度25‑42℃;本发明利用该基因的重组质粒和重组工程菌在催化体系中直接催化合成L‑肌肽,提高了L‑肌肽的转化率,同时解决了氨肽酶法催化过程繁复的酶分离纯化和高成本的难题。
Description
技术领域
本发明涉及一种肌肽的合成方法,具体是一种直接采用重组大肠杆菌作为全细胞催化剂高效率合成L-肌肽的方法,属于生物生产技术领域。
背景技术
L-肌肽(β-丙氨酰-L-组氨酸)及其类似物(如高肌肽和鹅肌肽),是广泛存在于哺乳动物的大脑、肌肉和其他重要组织中的天然活性二肽。自该活性肽发现的一百多年来,已有大量的研究发现或者证明L-肌肽具有显著的抗氧化、消除胞内自由基、抗衰老等活性,并且在临床上用于高血压、心脏病、老年性白内障、溃疡、抗肿瘤、促进伤口愈合等方面的辅助治疗。由于其抗氧化的活性强,毒副作用低并具有多种生理活性,该活性肽及其衍生物在医药、保健、卫生、化妆品等领域已有广泛的应用,市场空间广阔。
目前L-肌肽的生产主要采用化学合成法。已有的化学合成方法比较多,主要可以分为两大类:(1)利用β-丙氨酸参与合成。其主要路线是β-丙氨酸经氨基保护、羧基活化后与保护的L-组氨酸缩合,然后脱掉保护基团得到L-肌肽。该路线由于各个保护基团的差异导致合成路线较多。其中常用的方法是利用邻苯二甲酸酐与β-丙氨酸生成邻苯二甲酰-β-丙氨酸保护氨基,羧基与氯化亚砜反应生成邻苯二甲酰-β-丙氨酰氯,再与保护的L-组氨酸形成肽键后脱保护基团得到产品。该路线比较复杂,收率低,肽键形成过程中易消旋,影响产品纯度,并且溶剂消耗大,易造成环境污染;(2)无β-丙氨酸参与的反应:主要原理为L-组氨酸先与不同的β-丙氨酸前体生成肽键,再进一步转换为肌肽。常用的路线是在醇钠作用下,L-组氨酸和氰乙酸乙酯发生酰化反应,得到氰基乙酰-L-组氨酸,经催化氢化还原得L-肌肽。该路线相对简单,省去对不同基团的保护和脱保护的过程,避免消旋反应的发生,但是需要无水操作,要求严格,并未工业化应用。同时,氰乙酸乙酯为环境毒害物质,易引起水体污染和毒性反应。
目前,已有采用温和环保的酶催化合成方法,以取代传统化学合成工艺的报道。如采用氨肽酶催化β-丙氨酸甲酯与L-组氨酸一步合成L-肌肽(申请公布号为CN107217048A的专利文献)。采用重组氨肽酶全细胞合成L-肌肽等方法的报道(Heyland J,N Antweiler,JLutz,et al.Simple enzymatic procedure for L-carnosine synthesis:whole-cellbiocatalysis and efficient biocatalyst recycling[J].Microbial Biotechnology,2010,3(1):74-83.)。然而,由于氨肽酶具有很高的外切酶活力,导致在反应体系中无法积累高浓度的L-肌肽。并且,利用氨肽酶合成L-肌肽对反应体系要求较高,往往需要水相和有机相体系,以减少产物的水解作用。但是有机相对酶的活力存在一定程度抑制,氨基酸底物在有机相中溶解度也较低,种种原因都导致基于氨肽酶合成L-肌肽的产量很低(最优结果是3.7g/L,Microbial Biotechnology,2010,3(1):74-83.)。除此之外,氨肽酶会形成三肽,导致反应产物复杂、提取纯化困难、L-肌肽得率较低(Heck T,V S Makam,J Lutz,etal.Kinetic Analysis of L-Carnosine Formation byβ-Aminopeptidases[J].AdvancedSynthesis&Catalysis,2010,352(2-3):407-415.)。并且,采用生物酶法制备、分离成本高昂,难以回收再利用,不利于大规模运用。
发明内容
本发明的目的是提供一种全细胞高效催化合成L-肌肽的方法,该方法通过重组氨基酸脂酰基转移酶作用将β-丙氨酸甲酯转酰基于L-组氨酸,形成L-肌肽,并通过基因工程的方法构建重组工程菌,实现全细胞催化和重复利用,以实现L-肌肽绿色、高效、低成本合成。
为了达到上述技术目的,本发明的技术方案是:
一种全细胞高效催化合成L-肌肽的方法,包括以下步骤:
(1)构建重组载体,所述重组载体含有核苷酸序列为SEQ ID NO.1所示(详见序列表)的氨基酸脂酰基转移酶基因,该基因编码的氨基酸序列如SEQ ID NO.2所示(详见序列表)。
(2)将核苷酸序列SEQ ID NO.1所示的基因转入大肠杆菌获得重组大肠杆菌。
本发明通过信号肽预测分析,发现该氨基酸脂酰基转移酶带有信号肽。进一步由蛋白质亚细胞定位预测分析软件分析发现该蛋白是胞外分泌蛋白。为避免蛋白表达后分泌到胞外,导致细胞催化活力下降。
具体地,将已知的氨基酸脂酰基核苷酸序列经密码子优化后通过基因合成获得编码23-616位氨基酸的基因片段SEQ ID NO.1,该片段5’、3’两端分别添加MscI和XhoI酶切位点;将合成基因片段和表达载体分别经MscI和XhoI酶切后,胶回收目的片段,目的片段经连接,连接产物转化大肠杆菌,在LB培养基上过夜培养,挑取单菌落培养后,获得重组大肠杆菌。
合成基因与表达载体经过酶切后,构建重组载体,优选的载体是pET22b。利用该载体携带的周质空间分泌信号肽序列,将重组蛋白表达后分泌到重组细胞的周质空间,以减少底物跨膜阻力,增加脂酰基转移酶与底物的结合机会,提高催化效率,同时有利于产物释放到细胞外,减少被胞内肽酶的降解几率。最终能显著提高L-肌肽的合成效率。
所述大肠杆菌包括所有根据现有技术可以作为宿主的大肠杆菌,优选但并不限于E.coli BL21(DE3)。
重组大肠杆菌发酵培养与基因诱导表达:所述重组大肠杆菌接种至含100μg/ml氨苄青霉素的LB培养基中,于37℃,220rpm过夜活化培养;将活化菌液接种至2.5L体积百分比为2%的LB培养基中,于37℃,300rpm,1.5vvm通气量,培养至OD600=0.6-0.8,加入终浓度为0.4mM IPTG,培养温度降为25℃继续培养10h,4℃离心发酵液收集菌体。
所述LB培养基包括酵母提取物5g/L,胰蛋白胨10g/L,NaCl 10g/L,pH值为7.2。
(3)将底物β-丙氨酸甲酯(β-Ala-OMe)以及L-组氨酸(L-His)溶于缓冲溶液,pH值为7.5-9.5。
β丙氨酸廉价易得,可以采用成熟工艺制备生产β-丙氨酸甲酯用作底物。L-组氨酸无需进行氨基保护,可以直接作为该方法的重组细胞底物。
(4)将重组大肠杆菌加入缓冲溶液中进行反应,反应温度25-42℃。反应适当时间,收集反应液离心分离菌体终止反应。
上述的合成方法,反应进行到适当程度时可以通过物理分离全细胞终止反应。分离获得的全细胞可以继续催化实现循环利用。
本发明利用来源于短隐杆菌的氨基酸脂酰基转移酶具有远优于氨肽酶合成L-肌肽的能力,并且无需提取纯化重组蛋白,反应体系简单,不需要使用有机溶剂。本发明利用该基因的重组质粒和重组工程菌在催化体系中直接催化合成L-肌肽,提高了L-肌肽的转化率,同时解决了氨肽酶法催化过程繁复的酶分离纯化和高成本的难题。
本发明的方法与现有的技术相比具有如下技术效果:
1)合成原料β-丙氨酸甲酯可以通过β-丙氨酸甲酯化快速合成,原料简单易得,成本较低;
2)全细胞催化合成路径简单环保,省去了复杂的酶分离纯化的步骤,全细胞可以通过固定化或物理分离多次循环使用,降低了生产成本;
3)水相反应体系,底物氨基酸溶解度高,对细胞毒性小,酶反应速率快,摩尔转化率高,不催化产物L-肌肽的水解反应,提高了生产效率,能显著降低生产成本,具有很高的应用潜力。
附图说明
图1为氨基酸脂酰基转移酶合成L-肌肽的反应示意图。
图2为全细胞循环利用的相对细胞活力示意图。
具体实施方式
下面结合附图和具体实施方式对本发明作进一步详细的说明。
本发明的L-肌肽生物合成路径简要描述为如图1所示,具体包括以下步骤:
一、氨基酸脂酰基转移酶表达载体及大肠杆菌的构建
根据已知的氨基酸脂酰基核苷酸序列(GenBank:BAK64661.1)经Jcat密码子优化后通过基因合成获得编码23-616位氨基酸的基因片段(SEQ ID NO.1)。该片段5’、3’两端分别添加MscI和XhoI酶切位点。将合成基因片段和pET22b载体分别经MscI和XhoI酶切后,胶回收目的片段,目的片段经连接,连接产物转化E.coli BL21(DE3),在含100μg/ml的LB培养基上过夜培养,挑取单菌落培养后,小量提取质粒酶切验证,获得重组大肠杆菌。
二、重组大肠杆菌发酵培养与基因诱导表达
将步骤一获得的重组大肠杆菌接种至含100μg/ml氨苄青霉素的LB培养基(酵母提取物5g/L,胰蛋白胨10g/L,NaCl 10g/L,pH=7.2)中,于37℃,220rpm过夜活化培养。将活化菌液接种至2.5L LB培养基中(2%,V/V),于37℃,300rpm,1.5vvm通气量,培养至OD600=0.6-0.8,加入终浓度为0.4mM IPTG,培养温度降为25℃继续培养10h,4℃离心发酵液收集菌体,作为本发明实施例中所用全细胞催化剂。
三、全细胞催化合成L-肌肽
称取0.698g酯盐酸盐(50mMβ-Ala-OMe)和1.55g L-组氨酸(100mM L-His),溶解于100mL,100mM,pH=8.5含10mM EDTA的硼酸盐缓冲溶液中。加入重组大肠杆菌细胞5g,于25℃混匀,振荡反应2h,离心终止反应,取样进行L-肌肽定量测定,测得L-肌肽浓度为40.6mM,摩尔转化率为81.2%。
测定方法为:取适量体积反应液于15000g离心10min后,取上清液经适当稀释后,取30μl样品混于270μl 0.2M硼酸缓冲液(pH=9.0),加入300μl 1.5mg/ml FMOC-Cl乙腈溶液,室温放置10分钟,再加入300μl 4mg/ml盐酸金刚烷胺的乙腈:水(1:1)溶液,混匀,0.22μm滤膜过滤,上HPLC进行测定。
色谱分析条件:Zorbax ODS C18柱,上样量20μl;流动相组成:A:乙腈;B:50mM醋酸钠缓冲液pH4.2;检测波长263nm;流动相总流量1ml/min;柱温30℃;梯度洗脱程序:0-3min,34%A,66%B;3-10min,45%A,55%B;10-20min,60%A,40%B;20-30min,100%A;30-40min,100%A。
菌体重复利用合成L-肌肽
重组大肠杆菌按照步骤三反应结束后,离心收集菌体,重复该反应流程,通过测定各轮次L-肌肽的浓度计算相对活力,如图2所示。第一次循环利用的相对细胞活力为96.8%,第二次循环利用的相对细胞活力为94.4%,第三次和第四次循环利用的相对细胞活力分别为91.3%和86.3%。
上述实施例不以任何方式限制本发明,凡是采用等同替换或等效变换的方式获得的技术方案均落在本发明的保护范围内。
序列表
<110> 常熟理工学院
<120> 一种全细胞高效催化合成L-肌肽的方法
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1797
<212> DNA
<213> 短隐杆菌(Empedobacter brevis)
<400> 1
atggccatgc aggacgctaa agctgactct gcttacgttc gtgacaacta cgaaaaaatc 60
gaacaggtta tcccgatgcg tgacggtacc aaactgttca ccgctatcta ccagccgaaa 120
gacaaaacca aacagtaccc ggttctgctg aaccgtaccc cgtacaccgt tgctccgtac 180
ggtgttaacg aatacaaaaa atctctgggt aacttcccga ccgaaatgcg tgaaggtttc 240
atcttcgttt accaggacgt tcgtggtaaa tggatgtctg aaggtgaatt cgaagacgtt 300
cgtccgatca acccgtctaa atctaaaaaa gctatcgacg aatctaccga caccttcgac 360
accctggaat ggctggctaa aaacctgaaa aactacacca aaaaagctgg tatctacggt 420
atctcttacc cgggtttcta ctctaccatg tctctggtta actctcaccc gaccctgaaa 480
gctgtttctc cgcaggctcc ggttaccaac tggttcctgg gtgacgactt ccaccacaac 540
ggtgttctgt tcctgaacga ctctttctct ttcatgacct tcttcggtgt taaacgtccg 600
cagccgatca ccccggacaa aggtccgaaa cgtttcgaat acccgatcaa agacaactac 660
cgtttctacg cttctggttc tgttaaagaa ctgaaagaca aatacctgca ggacaacatc 720
aaattctaca acgacctgtt cgctcacccg gactacgacc agttctggca ggaccgtaac 780
gttctgccgc acctgaccaa cgttcagccg gctgttatga ccgttggtgg tttcttcgac 840
gctgaagacg tttacggtgc tttcgaaacc tacaaagcta tcgaaaaaca gaacccgaaa 900
gctaccaaca tcatggttgc tggtccgtgg ttccacggtg gttgggttcg ttctaacggt 960
tctaccttcg gtgacatgca gttcgcttct aacacctctg aacactacca gcaggaaatc 1020
gaactgccgt tcttcaacta ctacctgaaa gacaaaggta acttcaaacc gaccgaagct 1080
accatcttca tcaccggttc taacgaatgg aaacagttcg acgcttggcc gccgaaaaac 1140
gttaccaccc agaaaatcta cctgcagcag aacggtaaaa tcgctttcaa caaaaccaac 1200
accaccacca ccttcgacga atacgttgct gacccgaact ctccggttcc gtactctggt 1260
ggtgttctgg aaacccgttc tcgtgaatac atggttgacg accagcgttt cgcttctacc 1320
cgtccggacg ttatggttta ccagtctgac atcctgaccg aagacatcac cctggctggt 1380
ccggttatca accacctggt tgtttctacc accggtaccg acgctgacta cgttgttaaa 1440
ctgatcgacg tttacccgga aaacaccccg aaattcaaca acaaactgat ggctggttac 1500
cagaacctga tccgtgctga aatcatgcgt ggtaaatacc gtaactcttt ctctaacccg 1560
gaagctatgg ttccgaacaa agaaaccaac gttacctaca ccatgccgga cgttggtcac 1620
accttcaaaa aaggtcaccg tatcatgatc caggttcaga actcttggtt cccgctggct 1680
gaccgtaacc cgcagcagtt catgaacgtt tacgaagcta cctctaaaga ctacctgaaa 1740
cagacccagc gtatctacca cacctcttac atcgaaatcc cggttctgaa actcgag 1797
<210> 2
<211> 595
<212> PRT
<213> 短隐杆菌(Empedobacter brevis)
<400> 2
Met Gly Ala Ala Leu Ala Ala Ser Ala Thr Val Ala Ala Ala Thr Gly
1 5 10 15
Leu Ile Gly Gly Val Ile Pro Met Ala Ala Gly Thr Leu Leu Pro Thr
20 25 30
Ala Ile Thr Gly Pro Leu Ala Leu Thr Leu Gly Thr Pro Val Leu Leu
35 40 45
Ala Ala Thr Pro Thr Thr Val Ala Pro Thr Gly Val Ala Gly Thr Leu
50 55 60
Leu Ser Leu Gly Ala Pro Pro Thr Gly Met Ala Gly Gly Pro Ile Pro
65 70 75 80
Val Thr Gly Ala Val Ala Gly Leu Thr Met Ser Gly Gly Gly Pro Gly
85 90 95
Ala Val Ala Pro Ile Ala Pro Ser Leu Ser Leu Leu Ala Ile Ala Gly
100 105 110
Ser Thr Ala Thr Pro Ala Thr Leu Gly Thr Leu Ala Leu Ala Leu Leu
115 120 125
Ala Thr Thr Leu Leu Ala Gly Ile Thr Gly Ile Ser Thr Pro Gly Pro
130 135 140
Thr Ser Thr Met Ser Leu Val Ala Ser His Pro Thr Leu Leu Ala Val
145 150 155 160
Ser Pro Gly Ala Pro Val Thr Ala Thr Pro Leu Gly Ala Ala Pro His
165 170 175
His Ala Gly Val Leu Pro Leu Ala Ala Ser Pro Ser Pro Met Thr Pro
180 185 190
Pro Gly Val Leu Ala Pro Gly Pro Ile Thr Pro Ala Leu Gly Pro Leu
195 200 205
Ala Pro Gly Thr Pro Ile Leu Ala Ala Thr Ala Pro Thr Ala Ser Gly
210 215 220
Ser Val Leu Gly Leu Leu Ala Leu Thr Leu Gly Ala Ala Ile Leu Pro
225 230 235 240
Thr Ala Ala Leu Pro Ala His Pro Ala Thr Ala Gly Pro Thr Gly Ala
245 250 255
Ala Ala Val Leu Pro His Leu Thr Ala Val Gly Pro Ala Val Met Thr
260 265 270
Val Gly Gly Pro Pro Ala Ala Gly Ala Val Thr Gly Ala Pro Gly Thr
275 280 285
Thr Leu Ala Ile Gly Leu Gly Ala Pro Leu Ala Thr Ala Ile Met Val
290 295 300
Ala Gly Pro Thr Pro His Gly Gly Thr Val Ala Ser Ala Gly Ser Thr
305 310 315 320
Pro Gly Ala Met Gly Pro Ala Ser Ala Thr Ser Gly His Thr Gly Gly
325 330 335
Gly Ile Gly Leu Pro Pro Pro Ala Thr Thr Leu Leu Ala Leu Gly Ala
340 345 350
Pro Leu Pro Thr Gly Ala Thr Ile Pro Ile Thr Gly Ser Ala Gly Thr
355 360 365
Leu Gly Pro Ala Ala Thr Pro Pro Leu Ala Val Thr Thr Gly Leu Ile
370 375 380
Thr Leu Gly Gly Ala Gly Leu Ile Ala Pro Ala Leu Thr Ala Thr Thr
385 390 395 400
Thr Thr Pro Ala Gly Thr Val Ala Ala Pro Ala Ser Pro Val Pro Thr
405 410 415
Ser Gly Gly Val Leu Gly Thr Ala Ser Ala Gly Thr Met Val Ala Ala
420 425 430
Gly Ala Pro Ala Ser Thr Ala Pro Ala Val Met Val Thr Gly Ser Ala
435 440 445
Ile Leu Thr Gly Ala Ile Thr Leu Ala Gly Pro Val Ile Ala His Leu
450 455 460
Val Val Ser Thr Thr Gly Thr Ala Ala Ala Thr Val Val Leu Leu Ile
465 470 475 480
Ala Val Thr Pro Gly Ala Thr Pro Leu Pro Ala Ala Leu Leu Met Ala
485 490 495
Gly Thr Gly Ala Leu Ile Ala Ala Gly Ile Met Ala Gly Leu Thr Ala
500 505 510
Ala Ser Pro Ser Ala Pro Gly Ala Met Val Pro Ala Leu Gly Thr Ala
515 520 525
Val Thr Thr Thr Met Pro Ala Val Gly His Thr Pro Leu Leu Gly His
530 535 540
Ala Ile Met Ile Gly Val Gly Ala Ser Thr Pro Pro Leu Ala Ala Ala
545 550 555 560
Ala Pro Gly Gly Pro Met Ala Val Thr Gly Ala Thr Ser Leu Ala Thr
565 570 575
Leu Leu Gly Thr Gly Ala Ile Thr His Thr Ser Thr Ile Gly Ile Pro
580 585 590
Val Leu Leu
595
Claims (7)
1.一种全细胞高效催化合成L-肌肽的方法,其特征在于包括以下步骤:
(1)构建重组载体,所述重组载体含有核苷酸序列为SEQ ID NO.1所示的氨基酸脂酰基转移酶基因,该基因编码的氨基酸序列如SEQ ID NO.2所示;
(2)将核苷酸序列SEQ ID NO.1所示的基因转入大肠杆菌获得重组大肠杆菌;
(3)将底物β-丙氨酸甲酯以及L-组氨酸溶于缓冲溶液,pH值为7.5-9.5;
(4)将重组大肠杆菌加入缓冲溶液中进行反应,反应温度25-42℃。
2.根据权利要求1所述的一种全细胞高效催化合成L-肌肽的方法,其特征在于:在所述步骤(1)、(2)中,将已知的氨基酸脂酰基核苷酸序列经密码子优化后通过基因合成获得编码23-616位氨基酸的基因片段SEQ ID NO.1,该片段5’、3’两端分别添加MscI和XhoI酶切位点;将合成基因片段和表达载体分别经MscI和XhoI酶切后,胶回收目的片段,目的片段经连接,连接产物转化大肠杆菌,在LB培养基上过夜培养,挑取单菌落培养后,获得重组大肠杆菌。
3.根据权利要求2所述的一种全细胞高效催化合成L-肌肽的方法,其特征在于:所述表达载体为pET22b载体。
4.根据权利要求2所述的一种全细胞高效催化合成L-肌肽的方法,其特征在于:所述大肠杆菌为E.coli BL21(DE3)。
5.根据权利要求2所述的一种全细胞高效催化合成L-肌肽的方法,其特征在于:所述重组大肠杆菌接种至含100μg/ml氨苄青霉素的LB培养基中,于37℃,220rpm过夜活化培养;将活化菌液接种至2.5L体积百分比为2%的LB培养基中,于37℃,300rpm,1.5vvm通气量,培养至OD600=0.6-0.8,加入终浓度为0.4mM IPTG,培养温度降为25℃继续培养10h,4℃离心发酵液收集菌体。
6.根据权利要求5所述的一种全细胞高效催化合成L-肌肽的方法,其特征在于:所述LB培养基包括酵母提取物5g/L,胰蛋白胨10g/L,NaCl 10g/L,pH值为7.2。
7.根据权利要求1所述的一种全细胞高效催化合成L-肌肽的方法,其特征在于:所述氨基酸脂酰基转移酶来源于短隐杆菌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910040744.9A CN109652484B (zh) | 2019-01-16 | 2019-01-16 | 一种全细胞高效催化合成l-肌肽的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910040744.9A CN109652484B (zh) | 2019-01-16 | 2019-01-16 | 一种全细胞高效催化合成l-肌肽的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109652484A true CN109652484A (zh) | 2019-04-19 |
CN109652484B CN109652484B (zh) | 2020-12-29 |
Family
ID=66120380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910040744.9A Active CN109652484B (zh) | 2019-01-16 | 2019-01-16 | 一种全细胞高效催化合成l-肌肽的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109652484B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110283859A (zh) * | 2019-07-15 | 2019-09-27 | 苏州富士莱医药股份有限公司 | 微生物酶法合成l-肌肽的方法 |
CN112480206A (zh) * | 2020-12-30 | 2021-03-12 | 音芙医药科技(上海)有限公司 | 一种l-肌肽的高效合成方法 |
CN113481252A (zh) * | 2021-08-11 | 2021-10-08 | 苏州富士莱医药股份有限公司 | 一步法催化合成l-肌肽的方法 |
CN115521956A (zh) * | 2022-10-21 | 2022-12-27 | 江苏诚信药业有限公司 | 一种生物酶催化合成l-肌肽的方法 |
CN115820610A (zh) * | 2022-09-29 | 2023-03-21 | 江南大学 | 氨肽酶重组菌、氨肽酶及其制备方法和应用 |
CN117486983A (zh) * | 2023-11-07 | 2024-02-02 | 苏州华赛生物工程技术有限公司 | L-肌肽制备方法即转运蛋白YjeM的新用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1371423A (zh) * | 1999-07-02 | 2002-09-25 | 藤泽药品工业株式会社 | 编码环状脂肽酰基转移酶的基因及其表达 |
CN107217048A (zh) * | 2017-07-10 | 2017-09-29 | 江苏诚信药业有限公司 | 一种催化合成肌肽的氨肽酶及其制备方法和应用 |
CN108048500A (zh) * | 2017-12-25 | 2018-05-18 | 大连医诺生物股份有限公司 | β-丙氨酸的生物合成方法 |
-
2019
- 2019-01-16 CN CN201910040744.9A patent/CN109652484B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1371423A (zh) * | 1999-07-02 | 2002-09-25 | 藤泽药品工业株式会社 | 编码环状脂肽酰基转移酶的基因及其表达 |
CN107217048A (zh) * | 2017-07-10 | 2017-09-29 | 江苏诚信药业有限公司 | 一种催化合成肌肽的氨肽酶及其制备方法和应用 |
CN108048500A (zh) * | 2017-12-25 | 2018-05-18 | 大连医诺生物股份有限公司 | β-丙氨酸的生物合成方法 |
Non-Patent Citations (1)
Title |
---|
杜庆: "天然抗氧化剂肌肽的研究进展", 《肉类研究》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110283859A (zh) * | 2019-07-15 | 2019-09-27 | 苏州富士莱医药股份有限公司 | 微生物酶法合成l-肌肽的方法 |
CN112480206A (zh) * | 2020-12-30 | 2021-03-12 | 音芙医药科技(上海)有限公司 | 一种l-肌肽的高效合成方法 |
CN113481252A (zh) * | 2021-08-11 | 2021-10-08 | 苏州富士莱医药股份有限公司 | 一步法催化合成l-肌肽的方法 |
CN115820610A (zh) * | 2022-09-29 | 2023-03-21 | 江南大学 | 氨肽酶重组菌、氨肽酶及其制备方法和应用 |
CN115820610B (zh) * | 2022-09-29 | 2023-12-08 | 江南大学 | 氨肽酶重组菌、氨肽酶及其制备方法和应用 |
CN115521956A (zh) * | 2022-10-21 | 2022-12-27 | 江苏诚信药业有限公司 | 一种生物酶催化合成l-肌肽的方法 |
CN115521956B (zh) * | 2022-10-21 | 2024-04-19 | 江苏诚信药业有限公司 | 一种生物酶催化合成l-肌肽的方法 |
CN117486983A (zh) * | 2023-11-07 | 2024-02-02 | 苏州华赛生物工程技术有限公司 | L-肌肽制备方法即转运蛋白YjeM的新用途 |
Also Published As
Publication number | Publication date |
---|---|
CN109652484B (zh) | 2020-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109652484A (zh) | 一种全细胞高效催化合成l-肌肽的方法 | |
CN109593805B (zh) | 一种利用l-氨基酸连接酶一步法合成l-肌肽的方法 | |
CN109851658B (zh) | 一种一步法合成l-肌肽的方法及截短的l-肌肽合成酶 | |
CN101914603B (zh) | 利用乳糖诱导pMFH载体生产重组蛋白的发酵方法 | |
CN109628435B (zh) | 一种纤维二糖差向异构酶突变体及其在产乳果糖中的应用 | |
CN107574159A (zh) | 一种以活性形式表达的谷氨酰胺转氨酶的突变体 | |
CN110382705A (zh) | 丙谷二肽的制备方法、丙谷二肽制备用酶及应用 | |
CN107384844A (zh) | 一种产磷脂酶d的重组大肠杆菌及其应用 | |
CN104152498A (zh) | 一种酶法生产α-酮戊二酸的方法 | |
CN104402975B (zh) | 抗衰老短肽及其制备方法 | |
CN110157653A (zh) | 一种高产环磷酸腺苷的重组大肠杆菌及其在合成环磷酸腺苷上的应用 | |
CN109943582A (zh) | 一种基于多巴胺脱羧酶催化产多巴胺的方法 | |
CN109609536A (zh) | 一种全细胞一步合成l-肌肽的方法 | |
CN102229934A (zh) | 猪小肠抗菌肽pr-39在毕赤酵母中的高效生产方法及应用 | |
CN104131041A (zh) | 一种α-酮戊二酸的生产方法 | |
CN108251346A (zh) | 一种表达透明质酸酶的重组谷氨酸棒杆菌及其应用 | |
CN112175971A (zh) | 密码子优化的krd基因和gdh基因及其应用 | |
CN112143688A (zh) | 一种重组大肠杆菌的构建及其应用 | |
CN111849937B (zh) | 川桑n-乙酰-5羟色胺转移酶snat5及其应用 | |
CN109295023B (zh) | 谷氨酸氧化酶突变体、核酸分子及应用和制备酮戊二酸的方法 | |
CN107326034A (zh) | 一种壳聚糖酶及其基因和应用 | |
RU2453604C1 (ru) | Гибридный белок (варианты), штамм бактерий escherichia coli - продуцент гибридного белка (варианты) и способ получения безметионинового интерферона альфа-2 человека | |
CN113832090B (zh) | 一种高产维生素k2的重组纳豆枯草芽孢杆菌,制备方法和用途 | |
CN105602922B (zh) | 一种泛生菌酰胺酶、基因、载体、工程菌及其应用 | |
CN111471667B (zh) | 壳聚糖酶Csn-PT及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220126 Address after: 215400 Building 1 and 2, No. 98, Zhaoxi Road, Shaxi Town, Taicang City, Suzhou City, Jiangsu Province Patentee after: Suzhou Bainuo Biotechnology Co.,Ltd. Address before: 215500 Changshou City South Three Ring Road No. 99, Suzhou, Jiangsu Patentee before: CHANGSHU INSTITUTE OF TECHNOLOGY |
|
TR01 | Transfer of patent right |